Insider Sale Details

On August 7, 2026, Jeffrey W. Albers, a director of Spyre Therapeutics Inc. (NASDAQ: SYRE), disposed of a total of 23,000 shares of the company’s common stock for an aggregate consideration of approximately $2,404,190, representing roughly $2.4 million. The transactions were executed pursuant to a Rule 10b5‑1 trading plan that the director adopted on April 16, 2026.

The sale was structured in three tranches:

  • Direct sale of 5,000 shares at a weighted‑average price of $104.47 per share (price range $103.59‑$105.65).
  • Indirect sale of 8,000 shares through Sessions LLC at a weighted‑average price of $104.38 per share (price range $103.52‑$105.54).
  • Indirect sale of 10,000 shares through Sessions LLC at a weighted‑average price of $104.68 per share (price range $103.60‑$106.01).

Prior to the disposals, Albers exercised stock options to acquire 5,000 shares at an exercise price of $10.39 per share, costing $51,950, and subsequently sold those shares as part of the above transactions.

Following the August 7 transactions, Albers holds no shares directly. Through Sessions LLC he beneficially owns 9,360 shares. He also retains options to purchase an additional 45,000 shares, which vest in 36 equal monthly installments beginning on November 22, 2023, contingent upon his continued service with the company.

Company Operational Update

In the same reporting period, Spyre Therapeutics announced positive Phase 2 data for its experimental drug SPY002 targeting moderately‑to‑severely active ulcerative colitis. The trial demonstrated a statistically significant 10.7‑point reduction in the Robarts Histopathology Index score at week 12.

Analyst Coverage Changes

Mizuho raised its price target for Spyre Therapeutics to $120, citing encouraging data from the SKYLINE Part A study that suggests a high probability of clinical remission superiority for both SPY001 and SPY002. Deutsche Bank also increased its target to $115 following a competitor’s (Abivax) trial setback. Conversely, Wolfe Research downgraded Spyre’s rating from Outperform to Peerperform, expressing concerns over valuation and uncertainty regarding forthcoming catalysts.

Additional Insider Activity

Fairmount Healthcare Fund II L.P., an entity linked to company directors, sold over 4.6 million shares of Spyre Therapeutics, effectively liquidating its holdings.

Market Context

At the time of the insider sale, Spyre Therapeutics’ share price was trading near its 52‑week high of $108.14, reflecting a 591 % total return over the preceding year. InvestingPro’s analysis classified the stock as among the most overvalued relative to its fair‑value estimate.